



**NON-INSURED HEALTH BENEFITS PHARMACY POLICY CHANGES:
PHARMACIST INITIATED TREATMENT FOR CONSTIPATION & CHANGE OF LISTING
STATUS FOR NALOXONE
Quebec Providers**

1. Pharmacist Initiating Treatment for constipation

Effective June 1, 2016, the NIHB Program will accept claims, which do not require prior approval, when pharmacists in Quebec initiate treatments to treat constipation for NIHB clients. The medications allowed for treating constipation are listed in AHFS class 56:12.00 of the NIHB DBL.

The NIHB Program requires providers to maintain documentation related to claims submitted for clients; at a minimum, this must include the following information:

- a) date ;
- b) name, and address or date of birth of the patient;
- c) proper name, common name, or brand name of the prescribed drug, and the quantity thereof;
- d) dosage;
- e) amount ; and
- f) signature of the licensed pharmacist.

Claims submitted will be reimbursed the drug cost and dispensing fee according to NIHB reimbursement policies. Pharmacist documentation must be available for review on audit. NIHB does not compensate pharmacists for client assessment services.

2. Change in listing status for naloxone

To improve access to treatment for opioid overdose, naloxone 0.4mg/mL 1mL products are now an open benefit in the DBL. The following DINs are included:

Drug	DIN	MFR
Naloxone 0.4mg/mL one mL ampoule	02148706	SDZ
Naloxone 0.4mg/mL one mL ampoule	02382482	ALV
Naloxone 0.4mg/mL one mL ampoule	02382601	SDZ
Naloxone 0.4mg/mL one mL vial	02393034	OMG

Where pharmacies are providing ancillary supplies to support safe naloxone administration and overdose management, providers can bill the cost of the naloxone and ancillary supplies as a “naloxone kit” under pseudo-DIN 09991460. Accepted contents in a naloxone kit include:

- 2 x one mL ampoules or vials of naloxone 0.4mg/ mL
- 2 alcohol swabs
- 2 safety syringes
- 1 rescue breathing mask
- 2 ampule breakers (if ampoules dispensed)
- 2 pairs of gloves

The ancillary items should not be billed separately from the naloxone. Please note that all claims are subject to audit verification.

Where NIHB clients are eligible to receive naloxone or a naloxone kit through other programs, providers are expected to coordinate claims per usual policy.